½ÃÀ庸°í¼­
»óǰÄÚµå
1404810

À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : NYHA Ŭ·¡½ºº°, ÃÖÁ¾ ¿ëµµº°, Á¦Ç° À¯Çüº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Implantable Cardioverter Defibrillators Market Size, Share & Trends Analysis Report By NYHA Class (NYHA Class I, NYHA Class II), By End-use (Hospitals, Ambulatory Surgical Centers), By Product Type, By Type, By Region, & Segment Forecasts, 2024-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 174 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é À̽ÄÇü Á¦¼¼µ¿±â ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 58¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 6.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Á¦Ç° ±â¼ú ¹ßÀü, °©ÀÛ½º·± ½ÉÀ帶ºñ À¯º´·ü Áõ°¡, ½ÉÀå °Ç°­¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÎ½Ä Áõ°¡, Á¤ºÎ ¹× ÀÇ·á±â°üÀÇ Áö¿ø Á¤Ã¥ µî ´Ù¾çÇÑ ¿äÀο¡ ±âÀÎÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ÀüüÀûÀ¸·Î Á¦¼¼µ¿±â ¼ö¿ä¸¦ °ßÀÎÇϰí Àüü ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÉÀåÀ絿±âÈ­ÀåÄ¡(CRT-D)¿Í À̽ÄÇü Á¦¼¼µ¿±â(ICD)¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä´Â ½ÉÇ÷°ü Áúȯ ¹× ±âŸ ½ÉÀå ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. °©ÀÛ½º·± ½ÉÀ帶ºñ(SCA)´Â ¿©ÀüÈ÷ ½É°¢ÇÑ »ç¸Á ¿øÀÎÀ¸·Î, ¹ß»ý·ü°ú °ü·Ã À§Çè ¿äÀÎÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÉºÎÀüÀº Àü ¼¼°è °Ç°­ ¹®Á¦¿¡ Å©°Ô ±â¿©Çϰí ÀÖÀ¸¸ç, CRT-D¿Í Á¦¼¼µ¿±âÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ ³ëÀΰú °ü»óµ¿¸ÆÁúȯ(CAD) ȯÀÚ¿¡¼­ ºñÁ¤»óÀûÀÎ ½ÉÀå ¸®µëÀÇ È®»êÀº ICD¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖÀ¸¸ç, CRT-D¿Í ICD´Â ½ÉÇ÷°ü ÁúȯÀÇ Ä¡·á¿Í ȯÀÚ ¿¹ÈÄ °³¼±¿¡ ÀÖ¾î ±× Á߿伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

ICD ½ÃÀåÀº COVID-19ÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ¼±ÅÃÀû ¼ö¼ú Áߴܰú COVID-19 ȯÀÚ¿¡ ´ëÇÑ ÁýÁßÀÌ 2020³â 1ºÐ±â ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª Àü¿°º´Àº ºÎÁ¤¸Æ ȯÀÚÀÇ ¿ø°Ý ¸ð´ÏÅ͸µÀ» Æ÷ÇÔÇÑ ¿ø°Ý ÀÇ·áÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çß½À´Ï´Ù. ½ÉÀ帮µëÇÐȸ°¡ ¹ßÇ¥ÇÑ °¡À̵å¶óÀÎÀº ´ë¸é Áø·á¸¦ Á¦ÇÑÇÏ°í ¿ø°Ý Áø·á¸¦ Àå·ÁÇÏ´Â °ÍÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÆ®·Î´ÐÀº ÀÌ·¯ÇÑ Æ®·»µå¸¦ Ȱ¿ëÇØ ÀçÅà ¸ð´ÏÅ͸µ ±â¼úÀÌ Å¾ÀçµÈ À̽ÄÇü CRM ÀåÄ¡¸¦ º¸±ÞÇß½À´Ï´Ù. ½ÉÇ÷°ü ¿ø°Ý ¸ð´ÏÅ͸µÀÇ ¼ºÀå¿¡µµ ºÒ±¸Çϰí, ÀϺΠEU ±¹°¡¸¦ Æ÷ÇÔÇÑ Æ¯Á¤ Áö¿ª¿¡¼­´Â »óȯÀÌ Á¦ÇѵǾî ÀÖ¾î Àüü ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¾à 13°³ Á¶»ç ´ë»ó ±¹°¡¿¡¼­´Â ½ÉºÎÀü °ü¸®¿Í °ü·ÃµÈ ¿ø°Ý ±â¼ú¿¡ ´ëÇÑ »óȯÀÌ ¾ÆÁ÷ ÀÌ·ç¾îÁöÁö ¾Ê°í ÀÖ½À´Ï´Ù.

À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ICD ½ÃÀåÀº Á¦Ç° À¯Çüº°·Î °æÁ¤¸Æ À̽ÄÇü Á¦¼¼µ¿±â(T-ICD)¿Í ÇÇÇÏ À̽ÄÇü Á¦¼¼µ¿±â(S-ICD)·Î ºÐ·ùµÇ¸ç, 2023³â T-ICD ºÎ¹®ÀÌ 89.83%ÀÇ ½ÃÀå Á¡À¯À²·Î ¿ìÀ§¸¦ Á¡Çß½À´Ï´Ù.
  • À¯Çüº°·Î º¸¸é ICD ½ÃÀåÀº ´Ü½É½Ç ICD, ¾ç½É½Ç ICD, ¾ç½É½Ç ICD, ¾ç½É½Ç ÀåÄ¡ ºÎ¹®ÀÌ 2023³â 44.33%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù.
  • NYHA Ŭ·¡½º¸¦ ±âÁØÀ¸·Î ½ÃÀåÀº NYHA Ŭ·¡½º II¿Í NYHA Ŭ·¡½º III·Î ºÐ·ùµÇ¸ç, NYHA Ŭ·¡½º II ºÎ¹®Àº 2023³â 67.72%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡ÇÏ°í ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø ±â°£ µ¿¾È 6.6%ÀÇ CAGR·Î °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ICD ½ÃÀåÀº ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó º´¿ø, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2023³â 86.67%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇßÀ¸¸ç, ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø ±â°£ µ¿¾È 6.5%ÀÇ °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â Àüü ½ÃÀå Á¡À¯À²ÀÇ 41.4%¸¦ Â÷ÁöÇÏ¸ç ¼¼°è ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ºÏ¹Ì´Â º´¿ø, Áø·á¼Ò, ÀÇ·á½Ã¼³ µî ¼±ÁøÀûÀÎ ÀÇ·á ÀÎÇÁ¶ó°¡ Àß ¹ß´ÞµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå º¯¼ö¿Í µ¿Çâ

  • À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á - ½É¹Ú ¸®µë °ü¸® µð¹ÙÀ̽º ½ÃÀå
    • ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀÇ ¿µÇ⠺м®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ±ÔÁ¦ ü°è
    • ±Ô°Ý°ú ÁذÅ
    • »óȯ ½Ã³ª¸®¿À
  • COVID-19 °¨¿°Áõ ÆÒµ¥¹ÍÀÇ ¿µÇâ
  • ½ÉºÎÀüÀ» ¾Î´Â ICD ȯÀÚ ¼ö
  • ¹èÅ͸® ±³È¯À» ¹Þ´Â ICD ȯÀÚÀÇ ºñÀ²°ú ÇÕº´Áõ ¹ß»ý·ü
    • ¹èÅ͸® ±³È¯À» ¹Þ´Â ICD ȯÀÚÀÇ ºñÀ²
    • ÇÕº´ÁõÀ²
  • ICD Ä¡·á¿¡ °üÇÑ ÀÓ»ó½ÃÇè Æò°¡
    • ½É±ÙÁõ(¹«½ºÆ½) ½ÃÇèÀÇ ´ÙºÎÀ§ ÀÚ±Ø
    • ´Ù½Ã¼³ °øµ¿ Insync ·£´ýÈ­ ÀÓ»ó Æò°¡(¹Ì·¯Å¬) ½ÃÇè
    • Hf(ÄÄÆÐ´Ï¾ð) ½ÃÇèÀÇ ¾à¹°¿ä¹ý, ÆäÀ̽Ì, Á¦¼¼µ¿ÀÇ ºñ±³
    • ½ÉÀåÀ絿±â-hf(Care-hf) ½ÃÇè
    • ½ÉÀåÀ絿±âÈ­Ä¡·á¸¦ ¼ö¹ÝÇÏ´Â ´Ù½Ã¼³ ÀÚµ¿ Á¦¼¼µ¿±â À̽Ä(Madit-crt) ½ÃÇè
    • ºñÇãÇ÷¼º ¼öÃà±â ½ÉºÎÀü »ç¸Á·ü·Î °íÅë¹Þ´Â ȯÀÚÀÇ À̽ÄÇü Á¦¼¼µ¿±â È¿À²À» Æò°¡ÇÏ´Â µ§¸¶Å©ÀÇ ¿¬±¸(µ§¸¶Å©) ½ÃÇè
    • ¿µ±¹ ½ÃÇè
  • ¾÷°è ºÐ¼® Åø
    • Porters ºÐ¼®
    • °Å½Ã°æÁ¦ ºÐ¼®

Á¦4Àå À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå : Á¦Ç° À¯Çü ºÐ¼®

  • Á¦Ç° À¯Çü º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • Á¦Ç° À¯Çüº°
  • °æÁ¤¸Æ À̽ÄÇü Á¦¼¼µ¿±â(T-ICD)
    • °æÁ¤¸Æ À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå, 2018-2030³â
  • ÇÇÇÏ À̽ÄÇü Á¦¼¼µ¿±â(S-ICD)
    • ÇÇÇÏ À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå, 2018-2030³â

Á¦5Àå À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå : À¯Çü ºÐ¼®

  • À¯Çü º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • À¯Çüº°
  • ½Ì±Û è¹ö ICD
    • ´Ü°­ ICD¸¦ »ç¿ëÇϴ ȯÀÚ¿¡°Ô ÀÚÁÖ ÀÖ´Â Áõ»ó
    • ½Ì±Û è¹ö ICD ½ÃÀå, 2018-2030³â
  • µà¾ó è¹ö ICD
    • À̰­ ICD¸¦ »ç¿ëÇϴ ȯÀÚ¿¡°Ô ÀÚÁÖ ÀÖ´Â Áõ»ó
    • µà¾ó è¹ö ICD ½ÃÀå, 2018-2030³â
  • ¾ç½É½Ç µð¹ÙÀ̽º
    • ¾ç½Ç µð¹ÙÀ̽º ½ÃÀå, 2018-2030³â

Á¦6Àå À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå : NYHA Ŭ·¡½º ºÐ¼®

  • NYHA Ŭ·¡½º º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • NYHA Ŭ·¡½ºº°
  • NYHA Ŭ·¡½º II
    • NYHA Ŭ·¡½º II ½ÃÀå, 2018-2030³â
  • NYHA Ŭ·¡½º III
    • NYHA Ŭ·¡½º III ½ÃÀå, 2018-2030³â

Á¦7Àå À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå : ÃÖÁ¾ ¿ëµµ ºÐ¼®

  • ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ÃÖÁ¾ ¿ëµµº°
  • º´¿ø
    • º´¿ø À¯Çü¿¡ ºÎÇÕÇÏ´Â ICD ÀÓÇöõÆ® º£¸®¿¡À̼Ç
    • º´¿ø ½ÃÀå, 2018-2030³â
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
    • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ½ÃÀå, 2018-2030³â
  • ±âŸ
    • ±âŸ ½ÃÀå, 2018-2030³â

Á¦8Àå À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå : Áö¿ªº° Àü¸Á
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ÀÇ À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ºÐ¼®

  • ±â¾÷ ºÐ·ù
  • Participants'Overview
  • À繫 ½ÇÀû
  • Á¦Ç° º¥Ä¡¸¶Å©
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Ç ºÐ¼®
    • È÷Æ®¸Ê ºÐ¼®
  • Swot-analysis
    • Abbott
    • Medtronic
    • Biotronik Se &Co. Kg
    • Boston Scientific Corporation
    • Microport Scientific Corporation
    • Livanova Plc
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • Àü·« ¸ÅÇÎ
    • ÀμöÇÕº´
    • Á¦Ç° ¹ß¸Å
    • ÆÄÆ®³Ê½Ê°ú Çù¾÷
    • Á¦Ç° ½ÂÀÎ
    • ±âŸ
ksm 24.01.18

Implantable Cardioverter Defibrillator Market Growth & Trends:

The global implantable cardioverter defibrillator market size is projected to reach USD 5.86 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 6.4% from 2024 to 2030. The growth can be attributed to various factors, including advancements in product technology, the increasing prevalence of sudden cardiac arrest, growing public awareness about cardiac health, and supportive policies by governments and healthcare organizations. These factors collectively drive the demand for cardioverter defibrillators and contribute to the overall market expansion.

The global demand for cardiac resynchronization therapy devices (CRT-Ds) and implantable cardioverter defibrillators (ICDs) is fueled by the increasing prevalence of cardiovascular diseases and other heart ailments. Sudden cardiac arrest (SCA) remains a significant cause of mortality, with a rising incidence and associated risk factors. Heart failure contributes significantly to global health challenges and drives the need for CRT-Ds and defibrillators. In addition, the prevalence of abnormal heart rhythms, especially in older adults and individuals with coronary artery disease (CAD), further boosts the demand for ICDs. These factors highlight the growing importance of CRT-Ds and ICDs in addressing cardiovascular conditions and improving patient outcomes.

The ICD market was negatively impacted by the COVID-19 pandemic. The suspension of elective surgeries and the focus on COVID-19 patients affected the market during the first quarter of 2020. However, the pandemic accelerated the adoption of telehealth, including remote monitoring for patients with arrhythmias. Guidelines released by the Heart Rhythm Society emphasized limiting in-person visits and promoting remote care. Biotronik capitalized on this trend by promoting its implantable CRM devices with home monitoring technology. Despite the growth in cardiovascular remote monitoring, limited reimbursement in specific regions including some EU countries hindered the overall market expansion. Approximately 13 surveyed countries still do not provide reimbursement for remote technologies in the context of heart failure management.

Implantable Cardioverter Defibrillator Market Report Highlights:

  • Based on product type, the ICD market is classified into transvenous implantable cardioverter-defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillator segments (S-ICDs). The T-ICDs segment dominated the market in 2023 with a revenue share of 89.83%.
  • Based on type, the ICD market is classified into single-chamber ICDs, dual-chamber ICDs, and biventricular devices segments. The biventricular devices segment dominated the market in 2023 with a revenue share of 44.33%.
  • Based on NYHA Class, the market is classified into NYHA Class II and NYHA Class III. The NYHA Class II segment dominated the market with a 67.72% share in 2023 and is estimated to grow at the fastest CAGR of 6.6% during the forecast period.
  • Based on end-use, the ICD market is classified into hospitals, ambulatory surgical centers, and others. The hospitals segment dominated the market with a share of 86.67% in 2023 and is estimated to grow at the fastest CAGR of 6.5% during the forecast period.
  • In terms of region, the North America dominated the global market and accounted for 41.4% of the total market share in 2023. North America has a well-developed, advanced healthcare infrastructure, including hospitals, clinics, and medical facilities.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Product Type Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 Nyha Class Segment
      • 1.1.1.4 End-use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 GVR's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
      • 1.9.1.1 Research Scope And Assumptions
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Primary Sources
  • 1.12 List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot-1
  • 2.3 Segment Snapshot - 2
  • 2.4 Competitive Landscape

Chapter 3. Implantable Cardioverter Defibrillators Market Variables And Trends

  • 3.1 Implantable Cardioverter Defibrillators (ICD) Market Lineage Outlook
    • 3.1.1 Parent Market Outlook - Cardiac Rhythm Management Devices Market
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Impact Analysis
      • 3.2.1.1 Increasing Prevalence Of Cardiovascular Diseases & Other Heart Ailments
      • 3.2.1.2 Growing Technological & Product Development Activities
      • 3.2.1.3 Recognition Of Subcutaneous ICDs
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Product Recalls
      • 3.2.2.2 Gender & Regional Implantation Disparity And Cybersecurity Concerns
  • 3.3 Regulatory Framework
    • 3.3.1 Standards And Compliances
      • 3.3.1.1 North America
      • 3.3.1.2 Europe
      • 3.3.1.3 Asia Pacific (Apac)
      • 3.3.1.4 Latin America (Latam)
      • 3.3.1.5 Middle East & Africa (Mea)
    • 3.3.2 Reimbursement Scenario
      • 3.3.2.1 U.S.
      • 3.3.2.2 Canada
      • 3.3.2.3 Germany
      • 3.3.2.4 UK
      • 3.3.2.5 Japan
      • 3.3.2.6 Australia
      • 3.3.2.7 China
  • 3.4 Impact Of Covid-19 Pandemic
  • 3.5 Volume Of ICD Patients Suffering Heart Failure
  • 3.6 Percentage Of ICD Patients Undergoing Battery Change And Complication Rate
    • 3.6.1 Percentage Of ICD Patients Undergoing Battery Change
    • 3.6.2 Complication Rate
  • 3.7 Assessment Of Trials On ICD Therapies
    • 3.7.1 Multisite Stimulation In Cardiomyopathy (Mustic) Trial
    • 3.7.2 Multicenter Insync Randomized Clinical Evaluations (Miracle) Trial
    • 3.7.3 Comparison Of Medical Therapy, Pacing, And Defibrillation In Hf (Companion) Trial
    • 3.7.4 Cardiac Resynchronization-hf (Care-hf) Trial
    • 3.7.5 Multicenter Automative Defibrillator Implantation With Cardiac Resynchronization Therapy (Madit-crt) Trial
    • 3.7.6 The Danish Study To Accessess The Efficiency Of Implantable Cardioverter Defibrillators In Patients Suffering From Nonischemic Systolic Heart Failure Mortality (Danish) Trial
    • 3.7.7 British Trial
  • 3.8 Industry Analysis Tools
    • 3.8.1 Porter's Analysis
    • 3.8.2 Macroeconomic Analysis

Chapter 4. Implantable Cardioverter Defibrillators Market: Product Type Analysis

  • 4.1 Product Type Movement Analysis & Market Share, 2023 & 2030
  • 4.2 Implantable Cardioverter Defibrillators Market Estimates & Forecast, By Product Type (USD Million)
  • 4.3 Transvenous Implantable Cardioverter Defibrillators (T-ICDs)
    • 4.3.1 Transvenous Implantable Cardioverter Defibrillators Market, 2018 - 2030 (USD Million)
  • 4.4 Subcutaneous Implantable Cardioverter Defibrillators (S-ICDs)
    • 4.4.1 Subcutaneous Implantable Cardioverter Defibrillators Market, 2018 - 2030 (USD Million)

Chapter 5. Implantable Cardioverter Defibrillators Market: Type Analysis

  • 5.1 Type Movement Analysis & Market Share, 2023 & 2030
  • 5.2 Implantable Cardioverter Defibrillators Market Estimates & Forecast, By Type (USD Million)
  • 5.3 Single Chamber ICDs
    • 5.3.1 Common Conditions In Patients Using Single-chamber ICDs
    • 5.3.2 Single Chamber ICDs Market, 2018 - 2030 (USD Million)
  • 5.4 Dual Chamber ICDs
    • 5.4.1 Common Conditions In Patients Using Dual-chamber ICDs
    • 5.4.2 Dual Chamber ICDs Market, 2018 - 2030 (USD Million)
  • 5.5 Biventricular Devices
    • 5.5.1 Biventricular Devices Market, 2018 - 2030 (USD Million)

Chapter 6. Implantable Cardioverter Defibrillators Market: Nyha Class Analysis

  • 6.1 Nyha Class Movement Analysis & Market Share, 2023 & 2030
  • 6.2 Implantable Cardioverter Defibrillators Market Estimates & Forecast, By Nyha Class (USD Million)
  • 6.3 Nyha Class Ii
    • 6.3.1 Nyha Class Ii Market, 2018 - 2030 (USD Million)
  • 6.4 Nyha Class Iii
    • 6.4.1 Nyha Class Iii Market, 2018 - 2030 (USD Million)

Chapter 7. Implantable Cardioverter Defibrillators Market: End-use Analysis

  • 7.1 End-use Movement Analysis & Market Share, 2023 & 2030
  • 7.2 Implantable Cardioverter Defibrillators Market Estimates & Forecast, By End-use (USD Million)
  • 7.3 Hospitals
    • 7.3.1 Variation Of ICD Implants As Per The Type Of Hospital
    • 7.3.2 Hospitals Market, 2018 - 2030 (USD Million)
  • 7.4 Ambulatory Surgical Centers
    • 7.4.1 Ambulatory Surgical Centers Market, 2018 - 2030 (USD Million)
  • 7.5 Others
    • 7.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 8. Implantable Cardioverter Defibrillators Market: Regional Estimates & Trend Analysis

  • 8.1 Implantable Cardioverter Defibrillators Market: Regional Outlook
  • 8.2 North America
    • 8.2.1 North America Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 Key Country Dynamics
      • 8.2.2.2 U.S. Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Key Country Dynamics
      • 8.2.3.2 Technology Used By Vendors For Patient Monitoring In Canada
      • 8.2.3.3 Canada Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2 UK
      • 8.3.2.1 Key Country Dynamics
      • 8.3.2.2 Hypertension Cases In UK
      • 8.3.2.3 UK Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3 Germany
      • 8.3.3.1 Key Country Dynamics
      • 8.3.3.2 Germany Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4 France
      • 8.3.4.1 Key Country Dynamics
      • 8.3.4.2 France Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5 Italy
      • 8.3.5.1 Key Country Dynamics
      • 8.3.5.2 Causes Of Replacement According To Indication
      • 8.3.5.3 Italy Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6 Spain
      • 8.3.6.1 Key Country Dynamics
      • 8.3.6.2 Spain Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7 Denmark
      • 8.3.7.1 Key Country Dynamics
      • 8.3.7.2 Denmark Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8 Sweden
      • 8.3.8.1 Key Country Dynamics
      • 8.3.8.2 Sweden Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9 Norway
      • 8.3.9.1 Key Country Dynamics
      • 8.3.9.2 Norway Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Key Country Dynamics
      • 8.4.2.2 Japan Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 Key Country Dynamics
      • 8.4.3.2 China Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 Key Country Dynamics
      • 8.4.4.2 India Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5 Australia
      • 8.4.5.1 Key Country Dynamics
      • 8.4.5.2 Australia Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6 South Korea
      • 8.4.6.1 Key Country Dynamics
      • 8.4.6.2 South Korea Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7 Thailand
      • 8.4.7.1 Key Country Dynamics
      • 8.4.7.2 Thailand Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Key Country Dynamics
      • 8.5.2.2 Brazil Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Key Country Dynamics
      • 8.5.3.2 Mexico Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4 Argentina
      • 8.5.4.1 Key Country Dynamics
      • 8.5.4.2 Argentina Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6 Middle East & Africa (Mea)
    • 8.6.1 Mea Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2 South Africa
      • 8.6.2.1 Key Country Dynamics
      • 8.6.2.2 South Africa Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3 Saudi Arabia
      • 8.6.3.1 Key Country Dynamics
      • 8.6.3.2 Saudi Arabia Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4 UAE
      • 8.6.4.1 Key Country Dynamics
      • 8.6.4.2 UAE Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5 Kuwait
      • 8.6.5.1 Key Country Dynamics
      • 8.6.5.2 Kuwait Implantable Cardioverter Defibrillators Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Analysis

  • 9.1 Company Categorization
  • 9.2 Participants' Overview
  • 9.3 Financial Performance
  • 9.4 Product Benchmarking
  • 9.5 Company Market Position Analysis
    • 9.5.1 Heat Map Analysis
  • 9.6 Swot-analysis
    • 9.6.1 Abbott
    • 9.6.2 Medtronic
    • 9.6.3 Biotronik Se & Co. Kg
    • 9.6.4 Boston Scientific Corporation
    • 9.6.5 Microport Scientific Corporation
    • 9.6.6 Livanova Plc
  • 9.7 Company Market Share Analysis, 2023
  • 9.8 Strategy Mapping
    • 9.8.1 Mergers & Acquisitions
    • 9.8.2 Product Launch
    • 9.8.3 Partnerships & Collaborations
    • 9.8.4 Product Approvals
    • 9.8.5 Others
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦